There are 1105 resources available
618P - Impact of neoadjuvant radiotherapy on cancer-specific and overall survival in locally advanced malignant thymoma: A SEER database analysis
Presenter: Xiaoyan Li
Session: Poster Display session
Resources:
Abstract
619P - Pathologic complete response is the essential element for surgical modification after neoadjuvant chemo-immunotherapy for non-small cell lung cancer invading lobar bronchial orifice: A multicenter retrospective cohort study
Presenter: Hao Zhang
Session: Poster Display session
Resources:
Abstract
620P - Pembrolizumab with radiotherapy versus pembrolizumab alone in non-small cell lung cancer: A systematic review and meta-analysis
Presenter: Klarasita Wibowo
Session: Poster Display session
Resources:
Abstract
621P - Comparison of biweekly carboplatin plus nab-paclitaxel with concurrent radiotherapy followed by durvalumab consolidation in elderly and younger patients
Presenter: YASUHITO Nunomura
Session: Poster Display session
Resources:
Abstract
622P - Our experience comparing outcomes between pleurectomy and decortication and extended pleurectomy and decortication in a mixed Asian population of malignant mesothelioma patients
Presenter: Kai Jie Eng
Session: Poster Display session
Resources:
Abstract
623P - Thoracic oncology MDTC: A survey study on the perceptions and opinions of healthcare teams
Presenter: Alfred Patrick Mina
Session: Poster Display session
Resources:
Abstract
624P - Multi-omics reveals branched chain amino acid signatures as prognostic factors for immunotherapy efficacy in non-small cell lung cancer
Presenter: Liyuan Dai
Session: Poster Display session
Resources:
Abstract
631P - Exploratory biomarker analysis in EGFR mutated NSCLC patients who treated with atezolizumab plus bevacizumab and chemotherapy from phase III ATTLAS trial
Presenter: Hyunsu Kim
Session: Poster Display session
Resources:
Abstract
632P - RATIONALE-304 long-term outcomes: First-line tislelizumab (TIS) + chemotherapy (chemo) vs chemo for locally advanced or metastatic non-squamous (NSQ) NSCLC
Presenter: Zhiyong Ma
Session: Poster Display session
Resources:
Abstract
633P - Phase Ia/Ib trial of the HER2 tyrosine kinase inhibitor zongertinib (BI 1810631) in patients with HER2-driven solid tumors: Focus on Asian patients
Presenter: Kiyotaka Yoh
Session: Poster Display session
Resources:
Abstract